Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia
T-DM1 is a cost-effective and dominant strategy for the adjuvant treatment of residual invasive HER2+ early BC in Colombia, driven by cost savings from reduced high-cost recurrences. These findings support the adoption of T-DM1 to improve outcomes while ensuring efficient use of healthcare resources.
Authors
- Laura Prieto‐Pinto (ORCID: https://orcid.org/0000-0002-9489-2585)
- Daniel Samacá-Samacá (ORCID: https://orcid.org/0000-0002-0782-4315)
- Melissa Diaz-Puentes (ORCID: https://orcid.org/0000-0003-2297-1855)
- Juliana Saavedra
- Diego Ballén
- Milton Lombana
- Sergio Augusto Cáceres-Maldonado
Institutions
- Instituto Nacional de Cancerología (CO)
- Universidad Autónoma de Occidente (CO)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2026-02-17
- DOI
- https://doi.org/10.36469/001c.156056
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00